JTCS St. Jude Medical
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article

J Thorac Cardiovasc Surg 2007;134:856
© 2007 The American Association for Thoracic Surgery

General Thoracic Surgery

Discussion

The first 20% of the full text of this article appears below.

Dr Alex G. Little (Dayton, Ohio). I think we would all agree that any collection of this large number of patients deserves to be analyzed and thought about carefully. That said, I am going to get to three areas in which I have some questions. One is to make a statement with which I know you agree because of having had the opportunity to read your manuscript and your identification of the limitations. The statement is that the validity of any clinical review of patients with IA disease really is dependent on the accuracy of the staging process that classified those patients. That being said, I do not think the concern of some patients with actual stage III or II disease being included weakens your conclusions, because presumably on a random basis the patients would have been evenly distributed. However, I think it really undermines to the point of negating any observations about long-term survival of patients with IA disease because we just do not know that this is really a clean collection of patients with stage IA disease. Would you comment on that, please?

Dr Chang. Yes, I agree. If you look at the entire cohort, it is difficult to reach the conclusion that 5-year survival is 58% because of this issue of understaging. I think some of the predictors we looked at probably are valid. For example, . . . [Full Text of this Article]


Related Article

Factors predicting poor survival after resection of stage IA non–small cell lung cancer
Michael Y. Chang, Steven J. Mentzer, Yolonda L. Colson, Philip A. Linden, Michael T. Jaklitsch, Stuart R. Lipsitz, and David J. Sugarbaker
J. Thorac. Cardiovasc. Surg. 2007 134: 850-856. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by The American Association for Thoracic Surgery.